Skip to content
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP

LeMaitre Vascular Inc. LMAT

17 fiscal years on record · USD · FY2025 reported · SEC filings only
14 YEARS OF DIVIDEND GROWTH
$249.6M
▲ 13.5% YoY
$57.7M
▲ 31.1% YoY
$74.5M
▲ 100.4% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

LeMaitre Vascular is a global provider of medical devices and human tissue cryopreservation services largely used in the treatment of peripheral vascular disease, end-stage renal disease and cardiovascular disease. Its worldwide headquarters is located in Burlington, Massachusetts, with a European headquarters in Sulzbach, Germany, an Asia Pacific headquarters in Singapore, and additional sales offices across North America, Europe and Asia Pacific. During the year ended December 31, 2025, approximately 95% of the company's net sales were generated in territories in which it employs direct sales representatives. As of December 31, 2025, its sales force comprised 160 sales representatives and export managers in North America, Europe and Asia Pacific. The company had 655 employees, including 646 full-time employees, as of December 31, 2025. It was founded in 1983 by George D. LeMaitre, M.D., a vascular surgeon who designed and developed the LeMaitre Valvulotome.

Written from the business description in LEMAITRE VASCULAR, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth

USD 249.6M
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2025 · Revenue 249.6 · Net income 57.7
100M200M
2009201220152018202120242025
Compound annual growth
+15.6%
+14.0%
+12.3%
+10.5%
+40.9%
+22.2%
+22.2%
+16.3%
+39.4%
+19.4%
+19.6%
+13.6%
+17.0%
+16.1%
+17.5%
+18.1%
+18.7%
+20.3%
+14.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +14.0% a year over the five years to FY2025 — but profit grew faster: net income at +22.2%, earnings per share at +19.4%.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

23 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 27.2% · Net 23.1%
10%20%
200920172025
ROE
FY2025 · ROE 15.8%
5%10%15%
200920172025
Three returns, three denominators.

Each USD of equity produced 16 cents of profit this year.

Cash & shareholders

USD 18.1M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 74.5
30M60M
200920172025
Net buybacks $M Dividends $M
FY2025 · Dividends 18.1 · Net buybacks -5.0
10.0M20.0M-25.0M-50.0MDividendsNet buybacks
200920112013201520172019202120232025

USD 18.1M in dividends — 31% of the year's profit went back to shareholders.

Total assetsUSD 615.7M
EquityUSD 393.5M
CashUSD 28.2M
Current ratio12.89×

Equity funds 64% of total assets.

The 17-year record

17 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
LMAT, 17-year financial record
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.20.20.20.20.20.10.10.10.10.10.10.10.10.10.10.10.1
Operating income $B0.10.10.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
EBITDA $B0.10.10.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Income tax $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0−0.00.0
Net income $B0.10.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Free cash flow $B0.10.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
EPS, diluted $2.521.931.340.931.251.040.881.130.860.550.420.230.200.160.130.370.10
Dividend / sh $0.800.640.560.500.440.380.340.280.220.180.160.140.120.100.08◌◌
Payout %313341533536382424313759575958——
ROE %15.813.910.67.912.613.212.919.117.412.810.66.35.94.94.112.03.3
Shares out B0.020.02◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 83 reconciliationsAUDITED

Reconciled in 17 of the 17 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Two checks were skipped: EPS is not tagged before 2009. Two checks were skipped: revenue is not tagged before 2009.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
Data on record since2009

Share this section

Download image